Drug intelligence / Profile preview

HLK-R045

Development stage: Preclinical
Lead developer: Shenzhen Yaoxin Biotechnology
Modality: Small Molecules
Administration: Ophthalmic

Overview

HLK-R045 is a preclinical-stage small molecule therapeutic being developed by Shenzhen Yaoxin Biotechnology (Pharmacin) for the treatment of choroidal neovascularization (CNV). The drug is uniquely formulated as a topical eye drop, aiming to provide a non-invasive alternative to the standard-of-care intravitreal injections currently used to treat CNV-related conditions such as wet age-related macular degeneration (wAMD). HLK-R045 is designed to inhibit the pathological angiogenesis and vascular leakage in the choroid that leads to progressive vision loss.

Beyond the preview

Go deeper on HLK-R045.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HLK-R045.

Explore the full profile